Market Place
Sourcing Support
Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases
19 Dec 2023 //
PR NEWSWIRE
Impel works to stave off bankruptcy, puts itself up for sale
05 Oct 2023 //
FIERCE BIOTECH
Impel seeks loan leniency to avoid asset sale or bankruptcy
16 Aug 2023 //
FIERCE BIOTECH
Impel to Present New Real-World Data for Trudhesa® at the 65th
15 Jun 2023 //
GLOBENEWSWIRE
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results
12 May 2023 //
GLOBENEWSWIRE
Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as CFO
10 May 2023 //
GLOBENEWSWIRE
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results
05 May 2023 //
GLOBENEWSWIRE
Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa
26 Apr 2023 //
GLOBENEWSWIRE
Impel Pharma Announces Appointment of Darren Cline to the Board of Directors
12 Apr 2023 //
GLOBENEWSWIRE
Impel to Present Data on Trudhesa Nasal Spray for Treatment of Acute Migraine
11 Apr 2023 //
GLOBENEWSWIRE
Impel Announces Fourth Quarter and Full Year 2022 Financial Results
24 Mar 2023 //
GLOBENEWSWIRE
Impel to Report Q4 and Full Year 2022 Financial Results on March 24, 2023
17 Mar 2023 //
GLOBENEWSWIRE
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
03 Mar 2023 //
GLOBENEWSWIRE
Impel, Cybin, EQRx trim head counts to prioritize easy wins
23 Feb 2023 //
FIERCE BIOTECH
Impel Pharmaceuticals Announces Strategic Reprioritization
22 Feb 2023 //
GLOBENEWSWIRE
Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Impel to Participate in Guggenheim 4th Annual Immunology and Neurology Day
08 Nov 2022 //
GLOBENEWSWIRE
Impel Pharmaceuticals to Report 3Q 2022 Financial Results
07 Nov 2022 //
GLOBENEWSWIRE
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in Sep
06 Sep 2022 //
GLOBENEWSWIRE
Impel Pharma Announces Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Impel Pharmaceuticals to Report Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Impel Pharma to Participate in 2022 Wedbush PacGrow Healthcare Conference
02 Aug 2022 //
GLOBENEWSWIRE
Impel Pharma Begins Dosing in PIIa Study Evaluating INP105 in ASD
19 Jul 2022 //
GLOBENEWSWIRE
Impel Pharmaceuticals: Under The Radar Despite Upside Potential
28 Jun 2022 //
SEEKING ALPHA
Impel Pharmaceuticals to Present Trudhesa Data at the 64th Annual Meeting of AHS
09 Jun 2022 //
GLOBENEWSWIRE
Impel Pharmaceuticals Announces First Quarter 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
Impel Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
12 May 2022 //
GLOBENEWSWIRE
Impel Pharmaceuticals to Report First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Impel leverages big-time migraine campaigns from competitors AbbVie, Biohaven
25 Apr 2022 //
ENDPTS
Impel Neuropharma Announces Company Will Now Be Known as Impel
25 Apr 2022 //
GLOBENEWSWIRE
Impel NeuroPharma to Ring Nasdaq Closing Bell on Monday, April 25
21 Apr 2022 //
GLOBENEWSWIRE
Impel NeuroPharma To Present At The 21st Annual Needham Healthcare Conference
07 Apr 2022 //
GLOBENEWSWIRE
Impel NeuroPharma Announces Q4 and Full Year 2021 Financial Results
24 Mar 2022 //
GLOBENEWSWIRE
Impel Neuropharma says $100 M Royalty and Debt Financing Agreement With Oaktree
17 Mar 2022 //
GLOBENEWSWIRE
Impel NeuroPharma to Report Q4 and FY 2021 Financial Results
17 Mar 2022 //
GLOBENEWSWIRE
Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences
28 Feb 2022 //
GLOBENEWSWIRE
Impel NeuroPharma Provides Updates on Trudhesa Launch
18 Jan 2022 //
GLOBENEWSWIRE
Impel NeuroPharma to Present at the Guggenheim Securities 3rd Annual Neuro
09 Nov 2021 //
GLOBENEWSWIRE
Impel NeuroPharma Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray
28 Sep 2021 //
GLOBENEWSWIRE
Impel NeuroPharma prices $45M stock offering
10 Sep 2021 //
DRUGDELIVERYBUSINESS
Impel NeuroPharma Announces Pricing of $45.0 Million Public Offering
09 Sep 2021 //
BIOSPACE
FDA Approvals Roundup: Trudhesa, Brukinsa, Keytruda
08 Sep 2021 //
RAPS
Impel NeuroPharma Announces Launch of Proposed Public Offering
07 Sep 2021 //
GLOBENEWSWIRE
Impel NeuroPharma Announces Second Quarter 2021 Financial Results
16 Aug 2021 //
GLOBENEWSWIRE
Impel NeuroPharma Enters Into a $50M Debt Financing Agreement
07 Jul 2021 //
GLOBENEWSWIRE
Impel NeuroPharma to Present at the Raymond James Health Innovation Conference
16 Jun 2021 //
GLOBENEWSWIRE
Impel NeuroPharma migraine effort points to mind-gut connections
26 May 2021 //
FIERCEPHARMA
Impel NeuroMind migraine effort points to mind-gut connections
25 May 2021 //
FIERCEPHARMA
Impel NeuroPharma Partners With Veeva Systems to Build Integrated
10 Feb 2021 //
BUSINESSWIRE
Impel NeuroPharma Partners With Veeva Systems to Build Integrated, Digital-First
10 Feb 2021 //
BUSINESSWIRE
Impel Announces U.S. Food & Drug Administration Acceptance NDA For INP104
20 Jan 2021 //
PRNEWSWIRE
Impel NeuroPharma Announces USFDA Acceptance Of New Drug Application For INP104
20 Jan 2021 //
PRNEWSWIRE
Impel NeuroPharma Submits NDA for INP104 in Acute Migraine
10 Nov 2020 //
CONTRACT PHARMA
Impel Neuropharma Announces FDA Submission Of NDA For INP104
09 Nov 2020 //
PRNEWSWIRE
Impel Neuropharma Presents Data From Pivotal Ph3 Registration Study Of Inp104
08 Oct 2020 //
PRESSRELEASE
Mydecine Innovations Group Signs Definitive Agreement Acquisition of NeuroPharm
14 Jul 2020 //
PRNEWSWIRE
Impel NeuroPharma Announces Publication of Positive Results of SNAP 101
30 Jun 2020 //
PRNEWSWIRE
Impel NeuroPharma Announces Publication of Positive Results of SNAP 101 Study
30 Jun 2020 //
PRNEWSWIRE
Impel NeuroPharma Presents Data From INP104 Clinical Program In Acute Migraine
15 Jun 2020 //
PRNEWSWIRE
Impel NeuroPharma Announces Primary Objectives Ph3 INP104
10 Jun 2020 //
PRNEWSWIRE
